FLT3 and acute myeloid leukemia: Sorafenib has also been combined with azacitidine in a prospective trial for the treatment of relapsed/refractory FLT3-ITD+ AML with a response rate of 46%, but only seven patients in this study had received a prior allo-HCT (84) which precludes any conclusions about the specific efficacy of this combination in the post-transplant setting.